CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, ...

Peripheral artery disease affects approximately 236 million persons worldwide and is diagnosed with an ankle–brachial index of less than 0.90. Among older persons, 3.3% of those without peripheral ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s were linked to reduced risk for major adverse CV and limb events at 1 year in patients with moderate ...

Imagine putting your socks on one morning and noticing your big toe, which has been painful for a few weeks, has started turning black. A trip to your doctor ends in being referred urgently to a ...

Peripheral artery disease (PAD) is a common yet often overlooked cardiovascular condition that affects millions worldwide. Characterized by narrowed arteries that reduce blood flow to the ...

Please provide your email address to receive an email when new articles are posted on . Researchers presented a new subanalysis of the STRIDE trial. Ozempic improved walking distance in patients with ...

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being. This Collection invites primary research exploring disease mechanisms or providing insight into PAD ...

STATEN ISLAND, N.Y. — Staten Island University Hospital is shining a light on Peripheral Arterial Disease this fall, with a Vascular Disease Awareness Walk. Peripheral Arterial Disease (PAD) is a ...

A new research paper was published in Aging (Aging-US) on February 25, 2025, Volume 17, Issue 2, titled "Epidemiology and genetic determination of measures of peripheral vascular health in the Long ...